ITonis

ITonis Financing Cash Flow

The Net Financing Cash Flow of ITonis (ITNS) as of Nov 1, 2026 is 111,518.00 USD. In the previous year, Net Financing Cash Flow was 3,700.00 USD — a change of 2,914.00% (higher).

Financing Cash Flow

111,518.00USD

YoY

2,914.00%

Last updated:

Net Financing Cash Flow of ITonis is 2023 111,518.00 USD. Net Financing Cash Flow of ITonis was 2022 3,700.00 USD. It decreases by 2,914.00% higher compared to the previous year.

The ITonis Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2016
85,100.00 USD
Jan 1, 2017
78,824.00 USD
Jan 1, 2018
74,000.00 USD
Jan 1, 2019
52,500.00 USD
Jan 1, 2020
53,300.00 USD
Jan 1, 2021
40,000.00 USD
Jan 1, 2022
3,700.00 USD
Jan 1, 2023
111,518.00 USD
The ITonis Financing Cash Flow history
YEARFinancing Cash FlowYoY
111,518.00USD+2,914.00%
3,700.00USD-90.75%
40,000.00USD-24.95%
53,300.00USD+1.52%
52,500.00USD-29.05%
74,000.00USD-6.12%
78,824.00USD-7.37%
85,100.00USD-84.34%
543,568.00USD-3.12%
561,048.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

Net Financing Cash Flow of ITonis is 111,518.00 USD in 2023.

Net Financing Cash Flow of ITonis changed from 3,700.00 USD to 111,518.00 USD, representing a 2,914.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow ITonis since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's ITonis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ITonis

All Key Metrics — ITonis